Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
Open Access
- 29 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3), 198-204
- https://doi.org/10.1016/j.clml.2021.09.018
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)Journal of Clinical Oncology, 2013
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin LymphomaJournal of Clinical Oncology, 2013
- Brentuximab vedotinmAbs, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphomaBlood, 2012
- Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapyHaematologica, 2012
- Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphomaBlood, 2010
- Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphomaHaematologica, 2007
- Metabolism and mechanisms of action of bendamustine: Rationales for combination therapiesSeminars in Oncology, 2002
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993